Frontline Treatment Options for Primary MF

Srdan Verstovsek, MD, PhD, expands upon frontline treatment options for primary MF, including Janus kinase (JAK) inhibitors.

EP: 1.Introduction: A 52-Year-Old Woman with Intermediate-Risk Primary Myelofibrosis

EP: 2.Clinical Criteria and Tools for Diagnosis of Primary MF

EP: 3.Symptom Scoring Systems and Prognostic Risk Models for MF

EP: 4.Clinical Factors Impacting Risk Assessment, Prognosis, and Progression

Now Viewing

EP: 5.Frontline Treatment Options for Primary MF

EP: 6.Efficacy Data from Clinical Trials of Ruxolitinib in Primary MF

EP: 7.Safety Data on Ruxolitinib in Primary MF

EP: 8.JAK Inhibitors: Impact on Symptoms, Quality of Life, and Patient Outcomes in MF

EP: 9.Benefits of Clinical Trial Enrollment for Patients with MF

EP: 10.Risk of AML and Potential Use of Bone Marrow Transplant in Patients with MF

EP: 11.Considerations for Patient Follow-Up and Management

EP: 12.Remaining Unmet Needs and Future Directions in MF

Related Videos